Editorial: Appropriateness and safety of using cannabinoid and psychedelic medicines as treatments for psychiatric disorders.
Front Psychiatry May 12, 2023 DOI: 10.3389/fpsyt.2023.1191970 (opens in new tab) via PubMed Central
Summary
AI-generated from the abstractThis editorial discusses the appropriateness and safety of using cannabinoid and psychedelic medicines for treating psychiatric disorders, emphasizing the need for careful evaluation of their therapeutic potential and risks.
Study at a glance
| Characteristics | Editorial Peer reviewed |
|---|---|
| Key finding | Argues that the use of cannabinoid and psychedelic medicines for psychiatric disorders requires further rigorous research to assess their appropriateness and safety. |
Abstract
Editorial: Appropriateness and safety of using cannabinoid and psychedelic medicines as treatments for psychiatric disorders.